Canadian Adjuvant Initiative Workshop, March 26-27, 2013-Ottawa, Canada

  1. Get@NRC: Canadian Adjuvant Initiative Workshop, March 26-27, 2013-Ottawa, Canada (Opens in a new window)
DOIResolve DOI:
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for:
Journal titleHuman Vaccines and Immunotherapeutics
Pages519526; # of pages: 8
SubjectWart virus vaccine; bioprocess; Canada; CD8+ T lymphocyte; commercial phenomena; conference paper; drug approval; drug formulation; drug industry; drug legislation; experimental model; health care delivery; health care policy; human; immune response; immunogenicity; nonhuman; trend study; vaccination; vaccine production; veterinary medicine
AbstractNovel adjuvants hold the promise for developing effective modern subunit vaccines capable of appropriately modulating the immune response against challenging diseases such as those caused by chronic and/or intracellular pathogens and cancer. Over the past decade there has been intensive research into discovering new adjuvants, however, their translation into routine clinical use is lagging. To stimulate discussion and identify opportunities for networking and collaboration among various stakeholders, a Canadian Adjuvant Initiative Workshop was held in Ottawa. Sponsored by the National Research Council Canada, Canadian Institutes of Health Research and the Vaccine Industry Committee, a two day workshop was held that brought together key Canadian and international stakeholders in adjuvant research from industry, academia and government. To discover innovation gaps and unmet needs, the presentations covered a board range of topics in adjuvant development; criteria for selection of lead adjuvant candidates from an industry perspective, discovery research across Canada, bioprocessing needs and challenges, veterinary vaccines, Canadian vaccine trial capabilities, the Canadian regulatory framework and WHO formulation laboratory experience. The workshop concluded with a discussion on the opportunity to create a Canadian Adjuvant Development Network. This report details the key discussion points and steps forward identified for facilitating adjuvant development research in Canada. © 2014 Landes Bioscience.
Publication date
AffiliationNational Research Council Canada (NRC-CNRC); Human Health Therapeutics (HHT-TSH)
Peer reviewedYes
NPARC number21272251
Export citationExport as RIS
Report a correctionReport a correction
Record identifierfa885aa5-9207-45b1-8785-aca3b261fe65
Record created2014-07-23
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)